23 articles for PT Cheng
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.
Bristol-Myers Squibb
Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARa/¿ agonists.
Bristol-Myers Squibb Research and Development (R & D)
Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.
Bristol-Myers Squibb R & D
Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Bristol-Myers Squibb
Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.
Bristol-Myers Squibb Research and Development
Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation.
Bristol-Myers Squibb R & D
Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).
Bristol-Myers Squibb
Aminodiol HIV protease inhibitors. 2. 1,1-Dimethyl-2-hydroxyethyl carbamate derivatives with enhanced potency
TBA
Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.
Bristol-Myers Squibb Research and Development
Discovery, synthesis, and structure-activity studies of tetrazole based growth hormone secretagogues.
Bristol-Myers Squibb Pharmaceutical Research Institute
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformations.
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.
Bristol-Myers Squibb Pharmaceutical Research Institute
BMS-201620: a selective beta 3 agonist.
Bristol-Myers Squibb Pharmaceutical Research Institute
6,7-dihydropyrido[2,1-A]phthalazin-2-ones for the treatment and prophylaxis of hepatitis B virus infection
Hoffmann-La Roche
Tripeptides with non-code amino acids as potential serine proteases inhibitors.
Medical University of Bialystok